Literature DB >> 10567597

Co-prescription of H2 receptor blockers and proton pump inhibitors with warfarin in general practice.

A P Hungin1, G P Rubin, H O'Flanagan.   

Abstract

Acid-suppressing drugs and anticoagulants are used increasingly in general practice. Warfarin is potentiated by some acid-suppressing drugs, notably cimetidine and omeprazole, through interference of the cytochrome P450 system. This study aimed to ascertain the extent of co-prescribing of warfarin and acid-suppressing drugs in general practice. We conducted a retrospective survey of the records of all patients prescribed acid-suppressing drugs over a 2-year period to ascertain those who had also taken warfarin; we also made a cross-sectional survey of all patients on warfarin to ascertain those who had taken acid-suppressing drugs. From a general practice population of 45 574 patients in northern England, 3423 (7.5%) had been prescribed acid-suppressing drugs during the previous 24 months. Of 274 patients who had been on warfarin, 44 (16.1%) had also taken acid-suppressing drugs (26 H2 receptor blockers and 18 proton-pump inhibitors). The commonest reasons for anticoagulation were thrombo-embolic disease (40.9%), atrial fibrillation (36.4%), valvular heart disease (18.2%), and surgical prophylaxis (4.5%). The indications for concurrent acid-suppressing drugs were: 'dyspepsia' 38.6%, reflux 22.7%, oesophagitis 13.6%, duodenal ulcer 13.6%, gastric ulcer 4.5%, unknown 6.8%. There have been no studies from primary care to evaluate the possible clinical effects of the concomitant use of acid-suppressing drugs and warfarin; some fluctuations in coagulation control, particularly in patients taking the combinations intermittently, may be due to this.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567597      PMCID: PMC1741442          DOI: 10.1136/pgmj.75.890.721

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  4 in total

1.  Stereoselective interaction of omeprazole with warfarin in healthy men.

Authors:  T Sutfin; K Balmer; H Boström; S Eriksson; P Höglund; O Paulsen
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

Review 2.  Safety of proton pump inhibitors--an overview.

Authors:  R Arnold
Journal:  Aliment Pharmacol Ther       Date:  1994       Impact factor: 8.171

3.  A study of the interaction of omeprazole and warfarin in anticoagulated patients.

Authors:  P Unge; L E Svedberg; A Nordgren; H Blom; T Andersson; P O Lagerström; J P Idström
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

4.  The use of long-term acid-suppression therapy.

Authors:  G P Rubin; B Contractor; M G Bramble
Journal:  Br J Clin Pract       Date:  1995 May-Jun
  4 in total
  3 in total

1.  Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

Authors:  Gianluca Trifirò; Salvatore Corrao; Marianna Alacqua; Salvatore Moretti; Michele Tari; Achille P Caputi; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2006-07-06       Impact factor: 4.335

2.  Evaluation of risk factors in patients with vitamin K-dependent coagulopathy presumed to be caused by exposure to brodifacoum.

Authors:  Hee-Jeong Lee; Mi-Ra You; Woo-Ram Moon; Hyoung Sul; Choon-Hae Chung; Chi-Young Park; Sang-Gon Park
Journal:  Korean J Intern Med       Date:  2014-06-27       Impact factor: 2.884

Review 3.  Long-term management of GERD in the elderly with pantoprazole.

Authors:  Carlo Calabrese; Anna Fabbri; Giulio Di Febo
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.